COMMEMORATING WORLD CANCER DAY, ETANA REAFFIRMS COMMITMENT TO DEVELOPING CANCER TREATMENTS IN INDONESIA
Jakarta, 5 February 2025 – In commemoration of World Cancer Day, Etana Biotechnologies Indonesia (Etana) reaffirmed its commitment to providing high-quality and affordable cancer treatment solutions. As a local biopharmaceutical company, Etana continues to innovate in developing and producing medicines that are accessible to cancer patients across Indonesia.
Currently, Etana has produced Bevacizumab, a monoclonal antibody-based targeted therapy that works by inhibiting the growth of blood vessels in tumors. This marks an important milestone in cancer therapy.
“Etana is the first biopharmaceutical company in Indonesia to produce Bevacizumab through technology transfer,” said Randy Stevian, Business Development Therapeutic Director at Etana.
In addition to Bevacizumab, Etana is also developing more monoclonal antibody products to make cancer therapy more affordable. Looking ahead, the company plans to expand its portfolio of high-technology, locally manufactured cancer therapies. Etana also aims to broaden its export reach to ASEAN and Middle Eastern countries with its halal-certified facilities.
“We are optimistic that in the future, both Etana and other biopharmaceutical companies in Indonesia will be able to synergize and support the government in providing more affordable medicines while strengthening national resilience,” Randy stated.
Randy also emphasized Etana’s commitment to supporting the government in raising awareness about early cancer detection, which remains a major challenge in Indonesia.
“The greatest challenge is not only for the industry, but also in educating the public to access accurate information about cancer treatment,” he added.
As part of its efforts to improve access to cancer care, Etana actively collaborates with various stakeholders, including the government, medical associations, and organizations directly engaged with patients.
About Etana
Established in 2014, Etana is an Indonesian biopharmaceutical company that researches, manufactures and markets biological therapies for the Southeast Asian market. With a mission to serve patients by providing high quality, affordable, and innovative therapies, the company has built state-of-the-art local production facility that meet international and Indonesian FDA standards. The facility is able to produce biological therapy with halal certification from the Indonesian Ulema Council (MUI). Etana aspires to become a leading biopharmaceutical company in the ASEAN region through aggressive expansion in production capacity and product development, with a primary focus on oncology and vaccine products.
Etana is led by a local management team who come from various international and domestic educational backgrounds and have strong experience in the biopharmaceutical industry and are supported by a team of international investors and leading biopharmaceutical companies. Etana aims to provide innovative yet affordable therapies through local production, to support Indonesian government programs and larger market demands. Etana is currently a leading biotech company in Indonesia committed to the research and manufacture of monoclonal antibodies, mRNAs and other biological platforms. For more information on Etana, visit: www.id.etanabiotech.com.